We are live on ! Find out more
HIT

Health In Tech Inc

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 90%
Negative

Neutral
Seeking Alpha
1 month ago
Health In Tech, Inc. (HIT) Q1 2026 Earnings Call Transcript
Health In Tech, Inc. (HIT) Q1 2026 Earnings Call Transcript
Health In Tech, Inc. (HIT) Q1 2026 Earnings Call Transcript
Negative
MarketBeat
1 month ago
Health In Tech Q1 Earnings Call Highlights
Health In Tech NASDAQ: HIT reported first-quarter 2026 revenue growth and a wider loss as management said the company is intentionally increasing investment in sales distribution, carrier relationships and technology development to pursue a larger share of the self-funded health insurance market.
Health In Tech Q1 Earnings Call Highlights
Neutral
PRNewsWire
1 month ago
Health In Tech Reports First Quarter 2026 Financial Results
Reiterates Guidance for 2026 Annual Revenue Ranging between $45 Million and $50 Million STUART, Fla., May 13, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three months ended March 31, 2026.
Health In Tech Reports First Quarter 2026 Financial Results
Neutral
PRNewsWire
1 month ago
Health In Tech to Announce First Quarter 2026 Financial Results on May 13, 2026
STUART, Fla., April 30, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the first quarter ended March 31, 2026, following the close of market on Wednesday, May 13, 2026.
Health In Tech to Announce First Quarter 2026 Financial Results on May 13, 2026
Neutral
GlobeNewsWire
1 month ago
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy PONTE VEDRA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today announced a major regulatory milestone after successfully completing its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company's investigational first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT).
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Neutral
PRNewsWire
1 month ago
Health In Tech to Present at the Market Movers Investor Summit
STUART, Fla., April 21, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) (the "Company"), an AI-enabled InsurTech platform company, today announced that it will be participating in the Market Movers Investor Summit on Tuesday, May 5, 2026.
Health In Tech to Present at the Market Movers Investor Summit
Neutral
PRNewsWire
2 months ago
Health In Tech Announces Closing of $7.0 Million Private Placement
STUART, Fla., March 27, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced the closing of its previously announced private investment in public equity financing (the "PIPE"), resulting in gross proceeds of approximately $7.0 million before deducting placement agent fees and offering expenses.
Health In Tech Announces Closing of $7.0 Million Private Placement
Neutral
Seeking Alpha
2 months ago
Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript
Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript
Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript
Neutral
PRNewsWire
2 months ago
Health In Tech Announces $7.0 Million Private Placement
STUART, Fla., March 25, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the "PIPE") that is expected to result in gross proceeds of approximately $7.0 million before deducting placement agent fees and offering expenses.
Health In Tech Announces $7.0 Million Private Placement
Neutral
PRNewsWire
2 months ago
Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results
Full year 2025 Revenues of $33.3 million, up 71% YoY Full year 2025 Adjusted EBITDA of $4.1 million, up 81% YoY STUART, Fla., March 25, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results